AUTHORS
Adekunle Emmanuel Alagbe, MD, PhD, Christina M. Lalama2, Kimberly A. Hochstedler Webb3, Nydia Chien4, Lynda Little-Ihrig, BS5, Claudia Morris, MD6, Caterina Minniti, MD7, Payal C Desai8, Victor Gordeuk, MD9, Kenneth I Ataga, MD10, Mark T. T Gladwin, MD11, Sruti Shiva, PhD12, Kaleab Abebe13, Enrico M Novelli, MD14
AFFILIATIONS
1 University of Pittsburgh-School of Medicine Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
2 University of Pittsburgh-School of Medicine Center for Biostatistics & Qualitative Methodology (CBQM), Pittsburgh, Pennsylvania, United States
3 University of Pittsburgh-School of Medicine Center for Biostatistics & Qualitative Methodology (CBQM), Pittsburgh, Pennsylvania, United States
4 University of Maryland School of Medicine, Baltimore, Maryland, United States
5 University of Pittsburgh-School of Medicine Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
6 Emory University School of Medicine Division of Pediatric Emergency Medicine, Atlanta, Georgia, United States
7 Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States
8 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
9 University of Illinois at Chicago, Dwight, Illinois, United States
10 University of Tennessee Health Science Center, Memphis, Tennessee, United States
11 University of Maryland School of Medicine, Baltimore, Maryland, United States
12 University of Pittsburgh-School of Medicine Vascular Medicine Institute, Pittsburgh, Pennsylvania, United States
13 University of Pittsburgh-School of Medicine Center for Biostatistics & Qualitative Methodology (CBQM), Pittsburgh, Pennsylvania, United States
14 University of Maryland School of Medicine, Baltimore, Maryland, United States
ABSTRACT
Background. Chronic pain affects ~40% of adults with sickle cell disease (SCD) and may stem from inflammation driving peripheral and central sensitization. While systemic inflammation is a hallmark of SCD, the extent to which circulating inflammatory mediators directly contribute to chronic pain remains unclear. Riociguat, a soluble guanylate cyclase stimulator that enhances nitric oxide–cyclic guanosine monophosphate signaling, has demonstrated anti-inflammatory and vascular protective effects in preclinical SCD models. The STERIO-SCD trial was a phase 1/2, randomized, placebo-controlled study to evaluate the safety and tolerability of riociguat in adults with SCD and hypertension or proteinuria. In this exploratory biomarker analysis of STERIO-SCD, we examined whether 1) riociguat modulates inflammatory cytokines, 2) baseline cytokine profiles are associated with baseline chronic pain burden, and 3) specific biomarkers predict treatment response.
Methods. Plasma samples from 97 participants (riociguat, n = 50; placebo, n = 47) who underwent phlebotomy at baseline and week 12, were analyzed for 45 inflammatory cytokines. Chronic pain (pain severity and interference scores) was assessed using the Brief Pain Inventory (BPI), while organ function was evaluated by estimated glomerular filtration rate (eGFR), urine albumin-creatinine ratio (uACR), and left ventricular ejection fraction (EF). Linear regression models adjusted for baseline values and study site were used to analyze baseline cytokine-pain associations, treatment effects, and prognostic and predictive biomarkers. Multiple comparisons were controlled using the Benjamini-Hochberg (BH) false discovery rate at a threshold of 0.20 given the exploratory nature of this analysis. Cytokine values below the limit of detection were analyzed as binary (detectable vs. undetectable) where appropriate. Otherwise, due to skewness, cytokine values were log2 transformed.
Results. At baseline, higher matrix metalloproteinase-12 (MMP12) levels were independently associated with greater pain interference (mean increase = 0.90 per doubling; P = 0.003; BH P = 0.14). At week 12, compared with placebo, riociguat significantly reduced C-X-C motif chemokine ligand 12 (CXCL12, adj. log2 mean difference = -0.35; p < 0.001; BH P = 0.007), hepatocyte growth factor (HGF; -0.34; p = 0.002; BH P = 0.023), and tumor necrosis factor superfamily member 12 (TNFSF12; -0.26; p < 0.001; BH P = 0.016), indicating attenuation of systemic inflammation. However, cytokine changes were not associated with improvements in pain after adjustment for treatment arm, baseline pain, and study site. Several cytokine changes were instead associated with changes in cardiac function. Doubling of CCL7, complement factor 1 (CF1), CXCL8, interferon-gamma (IFN-γ), interleukin-6 (IL-6), oncostatin M (OSM), and transforming growth factor alpha (TGF-α) were associated with reduced EF, while TNFSF10 was associated with increased EF at 12 weeks (all p < 0.04, BH P < 0.19). Change in detectability of IL-2 was also associated with changes in EF (p < 0.001; BH P = 0.03); compared with participants whose IL-2 remained undetectable at week 12, those whose IL-2 became detectable experienced a reduction in EF. Detectability status for baseline IL-33 significantly modified the effect of riociguat on pain interference (interaction β = -4.17; p = 0.003; BH P = 0.13), suggesting greater treatment benefit in participants with detectable IL-33 vs. undetectable.
Conclusions. In this biomarker analysis of STERIO-SCD, riociguat significantly reduced levels of multiple inflammatory cytokines. Associations between cytokines and cardiac function support immune dysregulation as a contributor to SCD-related organ injury. In addition, baseline MMP12 was associated with pain burden, while IL-33 emerged as a candidate biomarker of riociguat response on pain interference; both findings require validation in larger cohorts. The absence of an effect of riociguat on pain could have been due to the parent trial not being powered for clinical efficacy endpoints, the relatively short duration of the treatment, limitations with BPI in SCD, inadequate magnitude of cytokine reduction, or the specific cytokines reduced by riociguat not being directly linked to pain in SCD. Despite these limitations, our findings identify candidate biomarkers for patient stratification and support future biomarker-guided therapeutic studies targeting inflammation in SCD.
DISCLOSURES
Adekunle Emmanuel Alagbe, MD, PhD: No relevant conflicts of interest to declare.